| |
Public Health Service Task Force
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States
|
| |
| |
October 12, 2006
Bear in mind that pharma companies have Patient Assistance Programs through which patients through their doctors can access ART drugs for no cost if they qualify, which means if they have no other way to reasonably access or pay for the drugs.
Table 3. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy
PROTEASE INHIBITORS
Recommended agents
Lopinavir/ritonavir (Kaletra0
Nelfinavir (Viracept)
Alternative agents
Indinavir
Ritonavir
Saquinavir-hard gel capsule (HGC) (Invirase)/ritonavir
Insufficient data to recommend use
Amprenavir
Atazanavir
Darunavir
Fosamprenavir
Tipranavir
NNRTIs
Recommended agents
Nevirapine
Not recommended
Efavirenz
Delavirdine
Fusion Inhibitors
Insufficient data to recommend use
Enfuvertide
NRTIs/
NtRTIs
Recommended agents
Zidovudine*
Lamivudine*
Alternate agents
Didanosine
Emtricitabine
Stavudine
Abacavir*
Insufficient data to recommend use
Tenofovir
Not recommended
Zalcitabine
|
|
| |
| |
|
|
|
